CD8A and melanoma: Even the highly cytotoxic tumor infiltrating lymphocytes (TIL) CD8+ cells infused up to 3x109 cells/kg in patients with melanoma did not induce serious adverse events (NCT01118091, NCT01236573).140 Altogether, these results suggest a low risk in receiving a high dose of CD8+ Tregs for patients.